Imaginab, Inc.

Tove Olafsen

David T Ho

Christian P Behrenbruch

Daulet Kadyl Satpayev

Giti Agahi

Jean M Gudas

Alessandro Mascioni

Arye Lipman

Michael Yuri Torgov

Jason Romero

Chio Mui Chan

Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.

Antigen binding constructs to CD8

Antigen binding constructs that bind to CD4, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD4, are described herein. Methods of use are described herein.

Antigen binding constructs to CD4

Provided herein are diabodies that comprise extension sequences and antigen binding constructs that comprise extension sequences.

Extension sequences for diabodies

Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.

Antigen binding constructs to target molecules

In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided.

J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use

Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.

Growing community of inventors

Reseda, CA, United States of America

Tove Olafsen